HK1042438A1 - Dds化合物及其測定方法 - Google Patents
Dds化合物及其測定方法Info
- Publication number
- HK1042438A1 HK1042438A1 HK02104211.3A HK02104211A HK1042438A1 HK 1042438 A1 HK1042438 A1 HK 1042438A1 HK 02104211 A HK02104211 A HK 02104211A HK 1042438 A1 HK1042438 A1 HK 1042438A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- assaying
- same
- dds compounds
- dds
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31013098 | 1998-10-30 | ||
| JP32927298 | 1998-11-19 | ||
| PCT/JP1999/006016 WO2000025825A1 (fr) | 1998-10-30 | 1999-10-29 | Composes dds et procede de dosage de ces composes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1042438A1 true HK1042438A1 (zh) | 2002-08-16 |
Family
ID=26566202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK02104211.3A HK1042438A1 (zh) | 1998-10-30 | 2002-06-03 | Dds化合物及其測定方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6811996B1 (zh) |
| EP (2) | EP1619210A1 (zh) |
| KR (1) | KR20010090602A (zh) |
| CN (2) | CN1191093C (zh) |
| AU (1) | AU765409B2 (zh) |
| BR (1) | BR9915198A (zh) |
| CA (1) | CA2348931A1 (zh) |
| EA (1) | EA003790B1 (zh) |
| HK (1) | HK1042438A1 (zh) |
| ID (1) | ID29943A (zh) |
| IL (1) | IL142842A0 (zh) |
| MX (1) | MXPA01004239A (zh) |
| NO (1) | NO20012128L (zh) |
| TW (1) | TWI232930B (zh) |
| WO (1) | WO2000025825A1 (zh) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| CA2333321A1 (en) * | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Drug complex |
| WO2000025825A1 (fr) * | 1998-10-30 | 2000-05-11 | Daiichi Pharmaceutical Co., Ltd. | Composes dds et procede de dosage de ces composes |
| WO2002000734A1 (fr) * | 2000-06-29 | 2002-01-03 | Daiichi Pharmaceutical Co., Ltd. | Compose dds et son procede de preparation |
| WO2005110277A2 (en) * | 2004-05-10 | 2005-11-24 | Michigan State University | Carboxylated polysaccharides and method of preparation and use |
| US9820986B2 (en) * | 2005-03-04 | 2017-11-21 | Taiwan Hopaz Chems, Mfg. Co., Ltd. | Glycopeptide compositions |
| WO2007034495A2 (en) * | 2005-09-22 | 2007-03-29 | Hadasit Medical Research Services & Development Limited | Dextran and arabinogalactan conjugates of therapeutically active compounds |
| CN1973902B (zh) * | 2006-12-12 | 2010-11-10 | 东北师范大学 | 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法 |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| ES2853204T3 (es) | 2010-05-25 | 2021-09-15 | Syndevrx Inc | Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos |
| TW201348244A (zh) * | 2012-05-23 | 2013-12-01 | Iner Aec Executive Yuan | 醣質藥物造影劑前驅物之合成方法 |
| KR102369419B1 (ko) | 2012-10-11 | 2022-03-02 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
| ES2782248T3 (es) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila |
| EA033912B1 (ru) | 2013-04-10 | 2019-12-09 | Синдевркс, Инк. | ИНГИБИТОРЫ MetAP2 И СПОСОБЫ ЛЕЧЕНИЯ ОЖИРЕНИЯ |
| PT3088419T (pt) | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| ES2727351T3 (es) | 2014-01-31 | 2019-10-15 | Daiichi Sankyo Co Ltd | Conjugado de fármaco-anticuerpo dirigido contra HER2 |
| WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| SG11201608309PA (en) | 2014-04-10 | 2016-11-29 | Daiichi Sankyo Co Ltd | Anti-her3 antibody-drug conjugate |
| IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
| CA3005450A1 (en) | 2015-12-10 | 2017-06-15 | Syndevrx, Inc. | Fumagillol derivatives and polymorphs thereof |
| CA3239447A1 (en) | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| JOP20170057B1 (ar) * | 2016-03-07 | 2022-03-14 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة كمركبات علاجية |
| JP6989521B2 (ja) | 2016-09-02 | 2022-01-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 標的化リガンド |
| JPWO2018066626A1 (ja) | 2016-10-07 | 2019-07-18 | 第一三共株式会社 | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 |
| TW201828993A (zh) | 2016-12-12 | 2018-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物與免疫檢查點抑制劑之組合 |
| TWI780104B (zh) | 2017-01-17 | 2022-10-11 | 日商第一三共股份有限公司 | 抗ｇｐｒ２０抗體及抗ｇｐｒ２０抗體-藥物結合物、以及其製造方法及用途 |
| TWI794230B (zh) | 2017-05-15 | 2023-03-01 | 日商第一三共股份有限公司 | 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法 |
| EP3677568A4 (en) | 2017-08-31 | 2021-05-12 | Daiichi Sankyo Company, Limited | INNOVATIVE PROCESS FOR THE PRODUCTION OF AN ANTIBODY-ACTIVE CONJUGATE |
| CA3073924C (en) | 2017-08-31 | 2023-10-17 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| EP3794041B1 (en) | 2018-05-18 | 2023-07-12 | Glycotope GmbH | Anti-muc1 antibody |
| EP3870231A1 (en) | 2018-10-26 | 2021-09-01 | Syndevrx, Inc. | Biomarkers of metap2 inhibitors and applications thereof |
| US11634508B2 (en) | 2019-07-10 | 2023-04-25 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| CA3146385A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| WO2024104186A1 (zh) * | 2022-11-17 | 2024-05-23 | 菲鹏生物股份有限公司 | 化合物及其制备方法和封闭剂 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386026A (en) * | 1981-04-20 | 1983-05-31 | Merck & Co., Inc. | Cell-specific glycopeptide ligands |
| JP2791001B2 (ja) | 1990-02-16 | 1998-08-27 | 株式会社ディ・ディ・エス研究所 | グリコシル−蛋白誘導体 |
| CA2081025A1 (en) | 1991-02-21 | 1992-08-22 | Kazuhiro Inoue | Carboxymethylmannoglucans and derivatives thereof |
| JP2589431B2 (ja) | 1991-05-13 | 1997-03-12 | 株式会社ディ・ディ・エス研究所 | 糖修飾ポリグルタミン酸誘導体及びその製造法 |
| JP2774417B2 (ja) | 1991-08-07 | 1998-07-09 | 株式会社ディ・ディ・エス研究所 | ペプチド骨格を有する分枝鎖型糖複合体及び微粒子キャリヤー |
| JP2589435B2 (ja) | 1991-09-17 | 1997-03-12 | 株式会社ディ・ディ・エス研究所 | 糖修飾ポリリジン誘導体 |
| JP2774429B2 (ja) | 1992-03-17 | 1998-07-09 | 株式会社ディ・ディ・エス研究所 | 糖骨格を有する分枝鎖型誘導体 |
| JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| ATE195324T1 (de) * | 1993-02-26 | 2000-08-15 | Drug Delivery System Inst Ltd | Polysaccharidderivat und wirkstoffträger |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| JPH0784481A (ja) | 1993-06-26 | 1995-03-31 | Ricoh Co Ltd | 画像形成装置 |
| GB2282384B8 (en) | 1993-08-18 | 1997-09-04 | Europ Economic Community | Drug delivery agents incorporating mitomycin |
| JP3418693B2 (ja) | 1993-09-06 | 2003-06-23 | 敏宏 赤池 | ポリ−ε−置換−Ｌ−リジンのＤ−ガラクトピラノシル−グルコン酸誘導体 |
| JPH07228688A (ja) | 1994-02-18 | 1995-08-29 | Yamanouchi Pharmaceut Co Ltd | 糖修飾ポリ−ω−置換−Ｌ−グルタミン酸誘導体およびその製造方法 |
| DE69530553T2 (de) * | 1994-05-13 | 2004-03-25 | KURARAY CO., LTD, Kurashiki | Medizinisches polymergel |
| JP3001381B2 (ja) | 1994-09-16 | 2000-01-24 | 株式会社ディ・ディ・エス研究所 | 臓器移行性を有する多糖誘導体および薬物担体 |
| US5886143A (en) * | 1994-12-07 | 1999-03-23 | Neorx Corporation | Hepatic-directed compounds and reagents for preparation thereof |
| JP3053764B2 (ja) | 1995-03-17 | 2000-06-19 | 財団法人神奈川科学技術アカデミー | 糖鎖高分子及びそれを用いた細胞処理剤並びに処理方法 |
| US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| CA2182851A1 (en) * | 1995-08-15 | 1997-02-16 | August Masaru Watanabe | Method for treating substance abuse withdrawal |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| US6368598B1 (en) * | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
| JP2001505194A (ja) * | 1996-11-05 | 2001-04-17 | ブリストル―マイヤーズ・スクイブ・カンパニー | 分枝ペプチド・リンカー |
| US6340461B1 (en) * | 1996-12-17 | 2002-01-22 | David Stephen Terman | Superantigen based methods and compositions for treatment of diseases |
| DE69833487T9 (de) * | 1997-06-12 | 2007-03-01 | Innovata Plc, Ruddington | Polymer-wirkstoff-konjugate zur behandlung von krebs |
| CA2333321A1 (en) | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Drug complex |
| WO2000025825A1 (fr) * | 1998-10-30 | 2000-05-11 | Daiichi Pharmaceutical Co., Ltd. | Composes dds et procede de dosage de ces composes |
-
1999
- 1999-10-29 WO PCT/JP1999/006016 patent/WO2000025825A1/ja not_active Application Discontinuation
- 1999-10-29 KR KR1020017005434A patent/KR20010090602A/ko not_active Application Discontinuation
- 1999-10-29 EA EA200100485A patent/EA003790B1/ru not_active IP Right Cessation
- 1999-10-29 AU AU64880/99A patent/AU765409B2/en not_active Ceased
- 1999-10-29 EP EP05015058A patent/EP1619210A1/en not_active Withdrawn
- 1999-10-29 EP EP99952805A patent/EP1155702A4/en not_active Ceased
- 1999-10-29 IL IL14284299A patent/IL142842A0/xx unknown
- 1999-10-29 CN CNB998152889A patent/CN1191093C/zh not_active Expired - Fee Related
- 1999-10-29 BR BR9915198-7A patent/BR9915198A/pt not_active Application Discontinuation
- 1999-10-29 MX MXPA01004239A patent/MXPA01004239A/es unknown
- 1999-10-29 CA CA002348931A patent/CA2348931A1/en not_active Abandoned
- 1999-10-29 US US09/807,980 patent/US6811996B1/en not_active Expired - Fee Related
- 1999-10-29 CN CN2004100115162A patent/CN1661044A/zh active Pending
- 1999-10-29 ID IDW00200101143A patent/ID29943A/id unknown
- 1999-10-30 TW TW091113738A patent/TWI232930B/zh not_active IP Right Cessation
-
2001
- 2001-04-30 NO NO20012128A patent/NO20012128L/no not_active Application Discontinuation
-
2002
- 2002-06-03 HK HK02104211.3A patent/HK1042438A1/zh unknown
-
2004
- 2004-04-13 US US10/822,661 patent/US7041818B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2348931A1 (en) | 2000-05-11 |
| EP1619210A1 (en) | 2006-01-25 |
| EP1155702A4 (en) | 2004-12-15 |
| AU765409B2 (en) | 2003-09-18 |
| KR20010090602A (ko) | 2001-10-18 |
| EA003790B1 (ru) | 2003-10-30 |
| MXPA01004239A (es) | 2002-06-04 |
| BR9915198A (pt) | 2001-08-14 |
| NO20012128D0 (no) | 2001-04-30 |
| EP1155702A1 (en) | 2001-11-21 |
| NO20012128L (no) | 2001-06-20 |
| TWI232930B (en) | 2005-05-21 |
| ID29943A (id) | 2001-10-25 |
| CN1191093C (zh) | 2005-03-02 |
| AU6488099A (en) | 2000-05-22 |
| WO2000025825A1 (fr) | 2000-05-11 |
| IL142842A0 (en) | 2002-03-10 |
| CN1661044A (zh) | 2005-08-31 |
| US6811996B1 (en) | 2004-11-02 |
| US20040192644A1 (en) | 2004-09-30 |
| CN1332640A (zh) | 2002-01-23 |
| US7041818B2 (en) | 2006-05-09 |
| EA200100485A1 (ru) | 2001-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL142842A0 (en) | Dds compounds and method for assaying the same | |
| HU9904702D0 (en) | Method for providing refrigeration | |
| GB9828640D0 (en) | Novel method and compounds | |
| GB9809414D0 (en) | Method | |
| GB9809776D0 (en) | Method | |
| EP1059760A4 (en) | BLOCK ENCRYPTION OF DISCRETE DATA | |
| GB9819764D0 (en) | Method | |
| GB9810722D0 (en) | Method | |
| GB9814055D0 (en) | Method | |
| GB9819769D0 (en) | Method | |
| GB9817266D0 (en) | Method | |
| GB9802475D0 (en) | Method | |
| GB9820185D0 (en) | Method | |
| GB9821225D0 (en) | Method | |
| ZA200104214B (en) | DDS compounds and method for assaying the same. | |
| GB9809780D0 (en) | Method | |
| GB9821038D0 (en) | Method | |
| GB9809782D0 (en) | Method | |
| GB9804355D0 (en) | Method | |
| GB9820474D0 (en) | Method for desensitisation | |
| GB9800445D0 (en) | Method for desensitisation | |
| GB9827521D0 (en) | Novel method and compounds | |
| GB9821974D0 (en) | Novel method and compounds | |
| GB9807810D0 (en) | Method | |
| GB9809293D0 (en) | Method |